×

Composition and method for treating neurological disease

DC
  • US 8,895,618 B1
  • Filed: 08/04/2014
  • Issued: 11/25/2014
  • Est. Priority Date: 11/24/2004
  • Status: Active Grant
First Claim
Patent Images

1. A dosage form suitable for once-daily administration to a human subject consisting of (i) 50 mg to 500 mg of a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, and (ii) at least one excipient, wherein the drug in the dosage form comprises an extended release form, and wherein the extended release form of the drug in the dosage form provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT provided by the same quantity of the drug in an immediate release form, wherein the dC/dT values are measured in a single dose human pharmacokinetic study over the time period between 0 and 4 hours after administration.

View all claims
  • 4 Assignments
Timeline View
Assignment View
    ×
    ×